Press Release: Lungpacer : Lungpacer Medical Announces Investigational Device Exemption (IDE) for STARI, Phase 2 Feasibility Clinical Trial
Lungpacer Medical is excited to announce approval of an Investigational Device Exemption (IDE) from the U.S. FDA for the STARI clinical study.
Read full article »
Lungpacer is a Canada-based medical device company that develops and commercializes intravenous catheter-based phrenic-nerve-pacing systems for the healthcare sector.
Read more